Hossain, Iftakher
Mohammadian, Mehrbod
Maanpää, Henna-Riikka
Takala, Riikka S. K.
Tenovuo, Olli
van Gils, Mark
Hutchinson, Peter
Menon, David K.
Newcombe, Virginia F.
Tallus, Jussi
Hirvonen, Jussi
Roine, Timo
Kurki, Timo
Blennow, Kaj
Zetterberg, Henrik
Posti, Jussi P.
Funding for this research was provided by:
The Finnish Medical Foundation
The Päivikki and Sakari Sohlberg Foundation
The Paulo Foundation
The Finnish Cultural Foundation
The Integra EANS Research Grant
University of Turku Graduate School funding
NIHR Research Professorship and the NIHR Cambridge BRC
NIHR Research UK
Academy of Medical Sciences / The Health Foundation Clinician Scientist Fellowship
personal grants from Emil Aaltonen Foundation sr
grants from the Swedish Research Council and the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement
Wallenberg Scholarship and grants from the Swedish and European Research Councils
Academy of Finland
Government’s Special Financial Transfer tied to academic research in Health Sciences
Maire Taponen Foundation sr
Article History
Received: 25 December 2022
Accepted: 10 June 2023
First Online: 15 August 2023
Declarations
:
: The Ethics Committee of the Hospital District of Southwest Finland approved the study protocol (Decision 68/180/2011). All patients or their next of kin were informed about the study both verbally and in writing. Written informed consent was obtained from all participants or their next of kin. All methods were carried out in accordance with the Declaration of Helsinki of the World Medical Association.
: Not applicable.
: Iftakher Hossain has no financial disclosures; Mehrbod Mohammadian has no financial disclosures; Henna-Riikka Maanpää has no financial disclosures; Riikka S.K. Takala has no financial disclosures. RSKT has received speakers fee from Abbott, Fresenius-Kabi, Orion and UCB, conference funding from Pfizer and Steripolar and is stockholder of Orion; Olli Tenovuo has no financial disclosures; Mark van Gils has no financial disclosures; Peter J. Hutchinson is supported by the UK NIHR and Royal College of Surgeons of England; David K. Menon reports collaborative research or consultancy agreements with GlaxoSmithKline Ltd; Ornim Medical; Shire Medical; Calico Inc; Pfizer Ltd; Pressura Ltd; Glide Pharma Ltd; NeuroTraumaSciences LLC; Lantasman AB; Virginia F. Newcombe holds a grant with Roche Pharmaceuticals; Jussi Tallus has no financial disclosures; Jussi Hirvonen has no financial disclosures; Timo Roine has no financial disclosures; Timo Kurki has no financial disclosures; Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program; Kaj Blennow has served as a consultant or at advisory boards for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program; Jussi P. Posti has no financial disclosures. JPP has received speaker’s fees from Orion corporation and Finnish Medical Association.